In the TCGA-PRAD cohort (Figure 4A), patients with high PRC1 expression had a hazard ratio (HR) of 1.95 (95% CI: 1.3–2.93, P = 0.002), indicating significantly shorter recurrence-free survival (RFS). The gene discussed is PRC1; the disease is prostate adenocarcinoma.